BioClinica and Kinapse Partner to Accelerate RBM Implementation

BioClinica®, Inc. has announced that it has partnered with Kinapse to accelerate Risk-Based Monitoring (RBM) implementation on global clinical trials using BioClinica's Compass Intelligent Monitoring solution.

"Implementing a comprehensive RBM solution can make a real difference in clinical research," BioClinica CEO John Hubbard said. "We're excited about this collaboration as it helps move the industry forward with intelligent monitoring by bringing together our technology and subject matter expertise with Kinapse's broad implementation experience."

Kinapse employs 450 professionals globally and has more than ten years of experience providing strategy and operations consultancy and capability-building programs, including RBM, to life sciences companies.

"In evaluating RBM-enabling technologies, we found BioClinica's Compass provides one of the most comprehensive solutions," said Stuart Donald, vice president of advisory services of Kinapse. "Compass is uniquely designed for RBM and has a rich tool set to solve risk and quality issues, making it the right technology in this new era of monitoring."

Kinapse's role includes easing the change management process as organizations transition to RBM. "We manage implementation from start to finish, including development of supporting processes," Donald said.

The partnership comes at a time of increasing demand for Compass and as several pilot studies using the technology show significant improvement in quality and risk reduction. BioClinica's Vice President of Clinical Innovation, Courtney McBean explained, "Compass catches issues that often go overlooked by onsite monitoring until later in the trial. Finding and fixing issues sooner is less costly and less risky than dealing with bigger problems down the road, especially when it comes to quality and safety."

BioClinica and Kinapse will make a joint presentation, Essential Steps to Successful Risk-Based Monitoring, on June 4 in Tokyo, Japan.

Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived.